(Q38229307)

31 August 2017

title

Tafamidis: a review of its use in familial amyloid polyneuropathy (English)

1 reference

31 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1

Lesley J Scott

1 reference

31 August 2017

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

12

1 reference

31 August 2017

page(s)

1371-1378

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0260-2

31 August 2017

exact match

0 references

cites work

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

FAP neuropathy and emerging treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Recent progress in the understanding and treatment of transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0260-2

Tafamidis (Vyndaqel): A Light for FAP Patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25022953

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0260-2

1 reference

Dimensions Publication ID

31 August 2017

1026806203

0 references

Fatcat ID

release_qb2yw2lvpbeahkzdgtyeadrf7a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qb2yw2lvpbeahkzdgtyeadrf7a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference